Hiroyuki Suzuki

List of Publications by Year
in descending order

56 papers	1,136 citations	430874 18 h-index	414414 32 g-index
58 all docs	58 docs citations	58 times ranked	1526 citing authors

#	Article	IF	Citations
1	Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet, The, 2019, 393, 1128-1137.	13.7	142
2	Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin. Pediatric Infectious Disease Journal, 2011, 30, 871-876.	2.0	121
3	T Cellâ€"Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease. Clinical Cancer Research, 2005, 11, 1521-1526.	7.0	92
4	Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer. Lung Cancer, 2015, 88, 310-318.	2.0	50
5	FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. International Journal of Oncology, 2015, 46, 999-1006.	3.3	47
6	Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 685-694.	1.0	44
7	Relation of Streptococcal Pyrogenic Exotoxin C as a Causative Superantigen for Kawasaki Disease. Pediatric Research, 2003, 53, 403-410.	2.3	42
8	Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease. Cytokine, 2012, 60, 681-685.	3.2	38
9	Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 127-134.	4.2	37
10	Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. Journal of Cancer Research and Therapeutics, 2016, 12, 945.	0.9	37
11	Serum levels of neutrophil activation cytokines in Kawasaki disease. Pediatrics International, 2001, 43, 115-119.	0.5	36
12	Analysis of results of surgery performed over a 20-year period on 500 patients with cancer of the thoracic esophagus. Surgery Today, 1996, 26, 77-82.	1.5	32
13	Prognostic Impact of Hypoxia-InduciblemiRNA-210in Patients with Lung Adenocarcinoma. Journal of Oncology, 2015, 2015, 1-8.	1.3	31
14	Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination. Cancer Immunology, Immunotherapy, 2018, 67, 949-964.	4.2	30
15	Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). BMJ Open, 2015, 5, e009562.	1.9	27
16	Detection of Multiple Superantigen Genes in Stools of Patients with Kawasaki Disease. Journal of Pediatrics, 2009, 155, 266-270.	1.8	26
17	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. World Journal of Surgical Oncology, 2016, 14, 238.	1.9	25
18	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. British Journal of Cancer, 2020, 122, 340-347.	6.4	24

#	Article	IF	Citations
19	Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease. Cardiovascular Research, 2021, 117, 96-108.	3.8	21
20	Changes in nuclear DNA and RNA during epidermal keratinization. Cell and Tissue Research, 1977, 184, 155-67.	2.9	17
21	Marker of Tâ€cell activation is elevated in refractory Kawasaki disease. Pediatrics International, 2010, 52, 785-789.	0.5	16
22	Recent advances in immunotherapy for non-small-cell lung cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 352-357.	3.3	16
23	Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 216-222.	1.1	13
24	Promotion of liver regeneration and antiâ€‘fibrotic effects of theÂTGFâ€‘Î² receptor kinase inhibitor galunisertib in CCl4â€‘treated mice. International Journal of Molecular Medicine, 2020, 46, 427-438.	4.0	13
25	Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma. Lung Cancer, 2017, 114, 23-30.	2.0	12
26	Expression of peanut agglutinin-binding carbohydrates correlates with nodal involvement in human lung adenocarcinoma. Cancer Letters, 2002, 187, 215-221.	7.2	10
27	Water retention in the acute phase of Kawasaki disease: relationship between oedema and the development of coronary arterial lesions. European Journal of Pediatrics, 2003, 162, 856-859.	2.7	10
28	Evaluation of Coronary Arterial Lesions Due to Kawasaki Disease Using Optical Coherence Tomography. Canadian Journal of Cardiology, 2014, 30, 956.e7-956.e9.	1.7	10
29	Prognostic impact of p53 protein overexpression in patients with node-negative lung adenocarcinoma. Cancer Letters, 2006, 237, 242-247.	7.2	9
30	The possible repositioning of an oral anti-arthritic drug, auranofin, for Nrf2-activating therapy: The demonstration of Nrf2-dependent anti-oxidative action using a zebrafish model. Free Radical Biology and Medicine, 2018, 115, 405-411.	2.9	9
31	Investigation of novel variations of ORAI1 gene and their association with Kawasaki disease. Journal of Human Genetics, 2019, 64, 511-519.	2.3	9
32	Intimal thickening and disruption of the media occur in the arterial walls of coronary arteries not associated with coronary arterial aneurysms in patients with Kawasaki disease. BMC Cardiovascular Disorders, 2021, 21, 278.	1.7	8
33	Neoplasms in three patients following Kawasaki disease. Pediatrics International, 2005, 47, 217-219.	0.5	7
34	Promotion of cellular senescence by THG-1/TSC22D4 knockout through activation of JUNB. Biochemical and Biophysical Research Communications, 2020, 522, 897-902.	2.1	7
35	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine, 2021, 10, 987.	2.4	7
36	Glycoprotein nonâ€“metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation. Cancer Science, 2021, 112, 4187-4197.	3.9	7

#	Article	IF	Citations
37	Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report. Case Reports in Oncology, 2016, 9, 51-55.	0.7	6
38	Quantitative analysis and clonal characterization of T-cell receptor Î² repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine. Oncology Letters, 2017, 14, 283-292.	1.8	6
39	Z-score is a possible predictor of the risk of coronary artery lesion development in patients with Kawasaki disease in Japan. European Journal of Pediatrics, 2021, 180, 2797-2805.	2.7	6
40	Detection of auto-antibodies against a 70ÂkDa protein derived from vascular smooth muscle cells in patients with Kawasaki disease. European Journal of Pediatrics, 2002, 161, 324-329.	2.7	5
41	Candida guilliermondii-induced chorioretinitis in a patient with eating disorder. Journal of Infection and Chemotherapy, 2021, 27, 642-646.	1.7	5
42	Î²-Cell-Specific Mafk Overexpression Impairs Pancreatic Endocrine Cell Development. PLoS ONE, 2016, 11, e0150010.	2.5	4
43	Generation of non-standard macrocyclic peptides specifically binding TSC-22 homologous gene-1. Biochemical and Biophysical Research Communications, 2019, 516, 445-450.	2.1	4
44	THG-1 suppresses SALL4 degradation to induce stemness genes and tumorsphere formation through antagonizing NRBP1 in squamous cell carcinoma cells. Biochemical and Biophysical Research Communications, 2020, 523, 307-314.	2.1	4
45	Role of PET/Computed Tomography in Radiofrequency Ablation for Malignant Pulmonary Tumors. PET Clinics, 2016, 11, 47-55.	3.0	3
46	Characteristics and outcomes of avoidant/restrictive food intake disorder in Japanese elementaryâ€school students on total parenteral nutrition. Pediatric Investigation, 2021, 5, 293-298.	1.4	3
47	Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan. JAMA Network Open, 2022, 5, e2216642.	5.9	3
48	Significance of testing for TP53 gene mutations in lung adenocarcinoma using targeted gene sequencing. Journal of Thoracic Disease, 2018, 10, S4147-S4150.	1.4	2
49	Case Report: Ciclosporin A for Refractory Multisystem Inflammatory Syndrome in Children. Frontiers in Pediatrics, 2022, 10, .	1.9	2
50	A 5-year survival case of so-called pulmonary carcinosarcoma with metastatic gastric tumor. The Journal of the Japanese Association for Chest Surgery, 2006, 20, 161-165.	0.0	1
51	A case of syndrome of inappropriate antidiuretic hormone (SIADH) after the resection of lung cancer. The Journal of the Japanese Association for Chest Surgery, 2006, 20, 180-183.	0.0	0
52	Ground-glass nodule in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-positive lung cancer: a case report. World Journal of Surgical Oncology, 2016, 14, 81.	1.9	0
53	A case of thoracoscopic resection of pulmonary alveolar soft part sarcoma.. The Journal of the Japanese Association for Chest Surgery, 2000, 14, 631-636.	0.0	0
54	CLINICAL CONSIDERATION CONCERNING SURGICAL TREATMENT FOR MALIGNANT TUMORS EXTENDING INTO THE HEPATIC INFERIOR VENA CAVA. The Journal of the Japanese Practical Surgeon Society, 1990, 51, 2405-2411.	0.0	0

#	Article	IF	Citations
55	Double Cancer of the Stomach and the Papilla of Vater. Progress of Digestive Endoscopy(1972), 1995, 47, 194-195.	0.0	0
56	Cyclosporin A for IVIG Nonresponders. , 2017, , 187-194.		0